Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 12, 1998, Pages 3193-3199

  Berry, Valerie ^a   Thorburn, Christine E ^a   Knott, Sarah J ^a,b   Woodnutt, Gary ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Wells Medical Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; ERYTHROMYCIN ETHYLSUCCINATE;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG POTENCY; HAEMOPHILUS INFLUENZAE; INFLUENZA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0031760851     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.12.3193     Document Type: Article

References (31)

1. Beghi, G., F. Berni, L. Carratu, A. Casalini, G. Consigli, M. D'Antò, V. Giogia, A. Molino, G. Paizis, and A. Vaghi. 1995. Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis. J. Chemother. 7:146-152.
2. Craig, W. A. 1996. Antimicrobial resistance issues of the future. Diagn. Microbiol. Infect. Dis. 25:213-217.
3. Craig, W. A. 1997. The future - can we learn from the past? Diagn. Microbiol. Infect. Dis. 27:49-53.
4. Craig, W. A., and D. Andes. 1996. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. J. 15:255-259.
5. Dabernat, H., C. Delmas, M. Seguy, J. B. Fourtillan, J. Girault, and M. B. Lareng. 1991. The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests. J. Antimicrob. Chemother. 27(Suppl. A):19-30.
6. Dagan, R., E. Leibovitz, M. Jacobs, D. Fliss, A. Lieberman, and P. Yagupsky. 1997. Bacteriologic response to acute otitis media (AOM) caused by Haemophilus influenzae (HI) treated with azithromycin (AZ), abstr. K102, p. 345. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Davey, P. G. 1991. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J. Hosp. Infect. 19(Suppl. A):29-37.
8. Davies, B. I., F. P. V. Maesen, and R. Gubbelmans. 1989. Azithromycin (CP-62,993) in acute exacerbations of chronic bronchitis: an open clinical, microbiological and pharmacokinetic study. J. Antimicrob. Chemother. 23: 743-751.
9. Drusano, G. L., and W. A. Craig. 1997. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J. Chemother. 9(Suppl. 3):38-44.
10. Foulds, G., R. M. Shepard, and R. B. Johnson. 1990. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25(Suppl. A):73-82.
11. Fraschini, F., F. Scaglioni, G. Pintucci, G. Maccarinelli, S. Dugnani, and G. Demartini. 1991. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. J. Antimicrob. Chemother. 27(Suppl. A):61-65.
12. Goldstein, F. W., M. F. Emirian, A. Coutrot, and J. F. Acar. 1990. Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae. J. Antimicrob. Chemother. 25(Suppl. A):25-28.
13. Grasso, S., G. Meinardi, I. DeCarneri, and V. Tamassia. 1978. New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob. Agents Chemother. 13:570-576.
14. Hardy, D. J., D. R. P. Guay, and R. N. Jones. 1992. Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological and clinical overview. Diagn. Microbiol. Infect. Dis. 15:39-53.
15. Hardy, D. J., D. M. Hensey, J. M. Beyer, C. Vojtko, E. J. McDonald, and P. B. Fernandes. 1988. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob. Agents Chemother. 32:1710-1719.
16. Hoepleman, A. I. M., A. P. Sips, J. L. M. van Helmond, P. W. C. van Barneveld, A. J. Neve, M. Zwinkles, M. Rozenberg-Arska, and J. Verhoef. 1993. A single-blind comparison of three-day azithromycin and ten-day coamoxiclav treatment of acute lower respiratory tract infections. J. Antimicrob. Chemother. 31(Suppl. E):147-152.
17. Holford, N. 1994. MK-MODEL, a quantitative modelling system for pharmacologists, version 5. Elsevicr-Biosoft, Cambridge, United Kingdom.
18. Jackson, D., D. L. Cooper, R. Horton, P. F. Langley, D. H. Staniforth, and J. A. Sutton. 1983. Absorption, pharmacokinetic and metabolic studies with Augmentin, p. 83-101. In E. A. P. Croydon and M. F. Michel (ed.), Augmentin: clavulanate-potentiated amoxycillin, Proceedings of the European Symposium. Excerpta Medica, Amsterdam, The Netherlands.
19. Jacobs, M. 1997. Respiratory tract infections: epidemiology and surveillance. J. Chemother. 9(Suppl. 3):10-17.
20. Josefsson, K., T. Bergan, and L. Magni. 1982. Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin hase. Br. J. Clin. Pharmacol. 13:685-691.
21. Loza, E., J. Matinez Beltran, F. Baquero, A. Leon, R. Canton, B. Garijo, and the Spanish Collaborative Group. 1992. Comparative in vitro activity of clarithromycin. Eur. J. Clin. Microbiol. Infect. Dis. 11:856-866.
22. Neu, H. C. 1991. The development of macrolides: clarithromycin in perspective. J. Antimicroh. Chemother. 27(Suppl. A):1-9.
23. O'Doherty, B. 1996. An open comparative study of azithromycin versus cefaclor in treatment of patients with upper respiratory tract infections. J. Antimicrob. Chemother. 37(Suppl. C):71-81.
24. Olsson-Liljequist, B., and B.-M. Hoffman. 1991. In vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against Haemophilus influenzae. J. Antimicrob. Chemother. 27(Suppl. A):11-17.
25. Pantiex, G., B. Guillaumond, R. Harf, A. Desbos, V. Sapin, M. Leclerq, and M. Perrin-Fayolle. 1993. In-vitro concentration of azithromycin in human phagocytic cells. J. Antimicrob. Chemother. 31(Suppl. E):1-4.
26. Retsema, J. A., J. M. Bergeron, D. Girard, W. B. Millisen, and A. E. Girard. 1993. Preferential concentration of azithromycin in an infected mouse thigh model. J. Antimicrob. Chemother. 31(Suppl. E):5-16.
27. Shepard, R. M., and F. C. Falkner. 1990. Pharmacokinetics of azithromycin in rats and dogs. J. Antimicrob. Chemother. 25(Suppl. A):49-60.
28. Smith, G. M., and K. H. Abbott. 1994. Development of experimental respiratory infections in neutropenic rats with either penicillin-resistant Streptococcus pneumoniae or β-lactamase-producing Haemophilus influenzae. Antimicrob. Agents Chemother. 38:608-610.
29. Sundberg, L., and A. Cederberg. 1994. Penetration of clarithromycin and its 14-hydroxy metabolite into middle ear effusion in children with secretory otitis media. J. Antimicrob. Chemother. 33:299-307.
30. Thompson, P. J., K. R. Burgess, and G. E. Martin. 1980. Influence of food on absorption of erythromycin ethyl succinate. Antimicrob. Agents Chemother. 12:157-162.
31. Zachariah, J. 1996. A randomised, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections. J. Antimicrob. Chemother. 37(Suppl):103-113.